Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia.
Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia.
复制标题
细胞表面抗原：儿童急性淋巴细胞白血病的预后意义。
DOI：
10.1182/blood.v55.3.395.395
复制
发表时间：
1980
期刊：
影响因子：
20.3
通讯作者：
S. Schlossman
中科院分区：
文献类型：
--
作者：
S. Sallan;J. Ritz;J. Pesando;R. Gelber;C. O'Brien;S. Hitchcock;F. Coral;S. Schlossman
通过免疫细胞表面标志物对 93 名急性淋巴细胞白血病 (ALL) 儿童的淋巴细胞进行了表征。这些患者接受单一方案治疗，在缓解期间接受阿霉素治疗，并随访 2 至 6.5 年（中位 4 年）。血清学上定义了三类患者：HTA+ Ia- CALLA-、Ia+ CALLA+ HTA- 和 Ia+ CALLA- HTA-。在免疫学子集中评估无病生存率和复发部位。与其他人的研究结果类似，T 细胞 (HTA+ Ia-) 患者与非 T 细胞 (Ia+ HTA-) 患者相比表现较差（中位无病生存期分别为 12 个月和 47 个月；p = 0.0004）。 HTA+ 患者的大多数复发发生在髓外部位。 Ia+ 患者中晚期睾丸复发很少见。此外，“共同 ALL 抗原”(CALLA) 可以识别 Ia+ 群体中相对有利的子集。将免疫标志物的预后价值与传统临床因素进行比较。 HTA+、老年和白细胞升高之间有很多重叠。然而，在 Ia+ 患者中，年龄和 WBC 本身都不具有预后意义。我们得出的结论是，表面标志物定义了生物学和预后特征。儿童 ALL 的病程必须在同质子集的背景下和特定的治疗方案中进行观察。
Lymphoblasts from 93 children with acute lymphoblastic leukemia (ALL) were characterized by immunologic cell surface markers. These patients were treated on a single protocol, featuring adriamycin therapy during remission, and have been followed from 2 to 6.5 yr (median 4 yr). Three classes of patients were defined serologically: HTA+ Ia- CALLA-, Ia+ CALLA+ HTA-, and Ia+ CALLA- HTA-. Disease-free survival and sites of relapse were assessed within immunologic subsets. Similar to the findings of others, T-cell (HTA+ Ia-) patients fared poorly as compared to non-T-cell (Ia+ HTA-) patients (median disease-free survival was 12 and 47 mo. respectively; p = 0.0004). The majority of relapses in the HTA+ patients occurred at extramedullary sites. Late testicular relapse was rare among Ia+ patients. In addition, the "common ALL antigen" (CALLA) may identify a relatively favorable subset within the Ia+ population. The prognostic value of the immunologic markers was compared with traditional clinical factors. There was much overlap between HTA+, older age, and elevated WBC. However, neither age nor WBC alone were of prognostic significance among the Ia+ patients. We conclude that surface markers define both biologic and prognostic characteristics. The course of childhood ALL must be viewed in the context of homogeneous subsets and within particular therapeutic programs.